Cargando…
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575482/ https://www.ncbi.nlm.nih.gov/pubmed/34778844 http://dx.doi.org/10.1016/S2665-9913(21)00351-9 |
| _version_ | 1784595688270594048 |
|---|---|
| author | Felten, Renaud Gallais, Floriane Schleiss, Cédric Chatelus, Emmanuel Javier, Rose-Marie Pijnenburg, Luc Sordet, Christelle Sibilia, Jean Arnaud, Laurent Fafi-Kremer, Samira Gottenberg, Jacques-Eric |
| author_facet | Felten, Renaud Gallais, Floriane Schleiss, Cédric Chatelus, Emmanuel Javier, Rose-Marie Pijnenburg, Luc Sordet, Christelle Sibilia, Jean Arnaud, Laurent Fafi-Kremer, Samira Gottenberg, Jacques-Eric |
| author_sort | Felten, Renaud |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8575482 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85754822021-11-09 Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab Felten, Renaud Gallais, Floriane Schleiss, Cédric Chatelus, Emmanuel Javier, Rose-Marie Pijnenburg, Luc Sordet, Christelle Sibilia, Jean Arnaud, Laurent Fafi-Kremer, Samira Gottenberg, Jacques-Eric Lancet Rheumatol Comment Elsevier Ltd. 2022-01 2021-11-08 /pmc/articles/PMC8575482/ /pubmed/34778844 http://dx.doi.org/10.1016/S2665-9913(21)00351-9 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Felten, Renaud Gallais, Floriane Schleiss, Cédric Chatelus, Emmanuel Javier, Rose-Marie Pijnenburg, Luc Sordet, Christelle Sibilia, Jean Arnaud, Laurent Fafi-Kremer, Samira Gottenberg, Jacques-Eric Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab |
| title | Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab |
| title_full | Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab |
| title_fullStr | Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab |
| title_full_unstemmed | Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab |
| title_short | Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab |
| title_sort | cellular and humoral immunity after the third dose of sars-cov-2 vaccine in patients treated with rituximab |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575482/ https://www.ncbi.nlm.nih.gov/pubmed/34778844 http://dx.doi.org/10.1016/S2665-9913(21)00351-9 |
| work_keys_str_mv | AT feltenrenaud cellularandhumoralimmunityafterthethirddoseofsarscov2vaccineinpatientstreatedwithrituximab AT gallaisfloriane cellularandhumoralimmunityafterthethirddoseofsarscov2vaccineinpatientstreatedwithrituximab AT schleisscedric cellularandhumoralimmunityafterthethirddoseofsarscov2vaccineinpatientstreatedwithrituximab AT chatelusemmanuel cellularandhumoralimmunityafterthethirddoseofsarscov2vaccineinpatientstreatedwithrituximab AT javierrosemarie cellularandhumoralimmunityafterthethirddoseofsarscov2vaccineinpatientstreatedwithrituximab AT pijnenburgluc cellularandhumoralimmunityafterthethirddoseofsarscov2vaccineinpatientstreatedwithrituximab AT sordetchristelle cellularandhumoralimmunityafterthethirddoseofsarscov2vaccineinpatientstreatedwithrituximab AT sibiliajean cellularandhumoralimmunityafterthethirddoseofsarscov2vaccineinpatientstreatedwithrituximab AT arnaudlaurent cellularandhumoralimmunityafterthethirddoseofsarscov2vaccineinpatientstreatedwithrituximab AT fafikremersamira cellularandhumoralimmunityafterthethirddoseofsarscov2vaccineinpatientstreatedwithrituximab AT gottenbergjacqueseric cellularandhumoralimmunityafterthethirddoseofsarscov2vaccineinpatientstreatedwithrituximab |